Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPCs in Diabetic Nephropathy and Type 2 Diabetes
NCT01843387Phase 2Completed
- Sponsor
- Mesoblast Ltd
- Start
- Jul 2013
- Primary completion
- Sep 2014
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rexlemestrocel-l in diabetic nephropathy (DN) (2 cohorts), sponsored by Mesoblast Ltd. Primary endpoint: Safety and tolerability of MPC therapy at 60 weeks. Started Jul 2013; status: completed.
02
Drugs
rexlemestrocel-l
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT01843387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01843387.